Analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to post ($0.57) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for aTyr Pharma’s earnings. aTyr Pharma reported earnings of ($0.65) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.3%. The company is expected to announce its next quarterly earnings results on Wednesday, August 9th.

On average, analysts expect that aTyr Pharma will report full-year earnings of ($2.32) per share for the current year, with EPS estimates ranging from ($2.34) to ($2.29). For the next fiscal year, analysts anticipate that the business will post earnings of ($3.11) per share, with EPS estimates ranging from ($3.29) to ($2.93). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow aTyr Pharma.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.06.

LIFE has been the topic of several research analyst reports. BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the company a “hold” rating in a research note on Saturday, March 18th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of aTyr Pharma in a research note on Saturday, March 18th. Finally, Citigroup Inc. lifted their target price on aTyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research note on Monday, March 20th.

Shares of aTyr Pharma (LIFE) traded down 1.35% on Thursday, hitting $3.65. 20,086 shares of the stock traded hands. The company’s 50 day moving average is $3.35 and its 200 day moving average is $3.20. aTyr Pharma has a one year low of $2.10 and a one year high of $4.45. The stock’s market cap is $86.89 million.

A number of large investors have recently bought and sold shares of LIFE. EcoR1 Capital LLC raised its stake in aTyr Pharma by 134.7% in the first quarter. EcoR1 Capital LLC now owns 2,292,659 shares of the biotechnology company’s stock valued at $8,024,000 after buying an additional 1,315,673 shares during the period. Renaissance Technologies LLC raised its stake in aTyr Pharma by 1.8% in the first quarter. Renaissance Technologies LLC now owns 38,800 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 700 shares during the period. Dimensional Fund Advisors LP raised its stake in aTyr Pharma by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 58,172 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 2,800 shares during the period. Geode Capital Management LLC raised its stake in aTyr Pharma by 0.4% in the first quarter. Geode Capital Management LLC now owns 112,178 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 444 shares during the period. Finally, Vanguard Group Inc. raised its stake in aTyr Pharma by 22.0% in the first quarter. Vanguard Group Inc. now owns 435,324 shares of the biotechnology company’s stock valued at $1,524,000 after buying an additional 78,579 shares during the period. Hedge funds and other institutional investors own 47.03% of the company’s stock.

TRADEMARK VIOLATION WARNING: “-$0.57 EPS Expected for aTyr Pharma, Inc. (LIFE) This Quarter” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/06/29/0-57-eps-expected-for-atyr-pharma-inc-life-this-quarter.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.